Csenge Advisory Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.47M Buy
23,252
+836
+4% +$117K 0.14% 137
2026
Q2
$2.83M Buy
22,416
+4,314
+24% +$568K 0.11% 164
2026
Q1
$2.52M Sell
18,102
-4,015
-18% -$562K 0.12% 159
2025
Q4
$2.71M Buy
22,117
+723
+3% +$87.9K 0.12% 152
2025
Q3
$2.37M Buy
21,394
+16,288
+319% +$1.85M 0.11% 158
2025
Q2
$562K Buy
+5,106
New +$543K 0.03% 398
2025
Q1
– Sell
-2,442
Closed -$226K – 692
2024
Q4
$226K Sell
2,442
-3,197
-57% -$288K 0.01% 629
2024
Q3
$479K Sell
5,639
-1,504
-21% -$115K 0.03% 433
2024
Q2
$490K Sell
7,143
-1,288
-15% -$86K 0.03% 407
2024
Q1
$618K Sell
8,431
-5,932
-41% -$456K 0.03% 380
2023
Q4
$1.16M Buy
14,363
+547
+4% +$42.6K 0.07% 210
2023
Q3
$1.04M Buy
13,816
+1,219
+10% +$93.8K 0.07% 205
2023
Q2
$971K Buy
12,597
+1,674
+15% +$134K 0.07% 217
2023
Q1
$906K Buy
10,923
+379
+4% +$31.4K 0.07% 226
2022
Q4
$905K Buy
10,544
+1,575
+18% +$125K 0.07% 228
2022
Q3
$553K Sell
8,969
-574
-6% -$36.2K 0.05% 313
2022
Q2
$590K Buy
9,543
+4,032
+73% +$250K 0.05% 311
2022
Q1
$328K Buy
+5,511
New +$352K 0.03% 480
2018
Q4
– Sell
-216
Closed -$15K – 680
2018
Q3
$15K Buy
+216
New +$16.3K 0.01% 419

Other funds holding GILD

Csenge Advisory Group's GILD Position: Q3 2026 in Review

Csenge Advisory Group increased its Gilead Sciences (GILD) stake by 3.7% in Q3 2026, buying an estimated $117K and bringing the position to 23,252 shares worth $3.47M. The position accounts for 0.14% of the portfolio, ranked #137.

Csenge Advisory Group first reported a position in GILD in Q3 2018 and has held it in 19 quarters since. 2,060 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Csenge Advisory Group held 23,252 shares of Gilead Sciences worth $3.47M as of Q3 2026.
  • Csenge Advisory Group bought 836 Gilead Sciences shares in Q3 2026, an estimated $117K.
  • Gilead Sciences made up 0.14% of Csenge Advisory Group's portfolio in Q3 2026, its #137 holding.
  • Csenge Advisory Group first reported a position in Gilead Sciences in Q3 2018 and has held it in 19 quarters since.
  • 2,060 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Csenge Advisory Group's 13F filing for Q3 2026, filed 4 Nov 2026.